Role of ciprofloxacin in patients with cholestasis after endoscopic retrograde cholangiopancreatography
| Autor: | Jerasak Wannaprasert, Pitchaya Prajanphanit, Kawin Leelawat, Thawee Ratanachu-ek, Somboon Subwongcharoen, Suchart Chantawibul, Sukij Panpimanmas |
|---|---|
| Rok vydání: | 2007 |
| Předmět: |
Adult
Male medicine.medical_specialty Cholangitis Gastroenterology digestive system law.invention Randomized controlled trial Cholestasis Anti-Infective Agents law Ciprofloxacin Clinical Research Internal medicine Medicine Bile Humans In patient Aged Cholangiopancreatography Endoscopic Retrograde Biliary drainage Endoscopic retrograde cholangiopancreatography medicine.diagnostic_test Bacteria business.industry Streptococcus viridans General Medicine Middle Aged medicine.disease digestive system diseases Surgery surgical procedures operative Relative risk Female business medicine.drug |
| Zdroj: | World journal of gastroenterology. 13(2) |
| ISSN: | 1007-9327 |
| Popis: | AIM: To determine the role of ciprofloxacin in reducing cholangitis in cholestatic patients with adequate biliary drainage after endoscopic retrograde cholangiopancreatography (ERCP). METHODS: A randomized, controlled trial was performed in 48 cholestatic patients at Rajavithi Hospital (Tertiary Referral Center for ERCP: 600 cases per year). All the 48 patients received 200 mg ciprofl oxacin intravenous injection for 30 min before starting any procedures, and then were randomly divided in two groups. Twenty-two patients in study group continually received ciprofl oxacin until 48 h after ERCP. Causes of biliary obstruction, bacteriology of bile and blood (in cholangitis) and clinical cholangitis were recorded. RESULTS: Forty-eight patients were enrolled and divided into continuous ciprofl oxacin treatment group (n = 22) and discontinuous ciprofl oxacin treatment group (n = 26). During ERCP, stones were found in 22 patients, malignant diseases in 24 patients and other pathologic lesions in 5 patients. One (4.5%) of the 22 patients who received ciprofl oxacin and 2 (6.3%) of the 26 patients who discontinued ciprofloxacin after ERCP developed cholangitis (relative risk = 0.71; 95% CI = 0.14-3.65; P = 0.88). Bacterobilia was found in 27 (56.3%) out of 48 patients. E. coli and Streptococcus viridans were the most common organisms. CONCLUSION: Continual use of ciprofloxacin in patients with cholestasis after adequate biliary drainage procedures plays no role in reducing cholangitis. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|